Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for...

|About: Cel-Sci Corporation (CVM)|By:, SA News Editor

Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for head and neck cancer is performing well in Phase 3 trials. "Based on everything that we've seen in the clinic so far, if we continue to see the same results, we will have the first non-toxic cancer therapy," Kersten tells eHealth Radio.